News

All Releases
JDRF and Tandem Diabetes Care Partner to Help Educate and Support the T1D Community
Jul 08, 2020
SAN DIEGO --(BUSINESS WIRE)--Jul. 8, 2020-- JDRF, the leading global organization funding type 1 diabetes (T1D) research, and Tandem Diabetes Care (NASDAQ: TNDM), a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary
Tandem Diabetes Care to Announce Second Quarter 2020 Financial Results on July 30, 2020
Jul 07, 2020
SAN DIEGO --(BUSINESS WIRE)--Jul. 7, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2020 results after the financial markets close on Thursday, July 30, 2020 .
Abbott and Tandem Diabetes Care Advance Development of Integrated Technologies for Future Automated Insulin Delivery Systems
Jun 29, 2020
- Companies partner to integrate Abbott's FreeStyle Libre continuous glucose monitoring technology with Tandem's insulin delivery products to provide options to simplify and tailor diabetes management ABBOTT PARK, Ill. and SAN DIEGO , June 29, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) and Tandem
Tandem Diabetes Care Acquires Sugarmate, a Popular Mobile App for People with Diabetes
Jun 24, 2020
SAN DIEGO --(BUSINESS WIRE)--Jun. 24, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its acquisition of Sugarmate, a popular mobile app for people with diabetes who use insulin.
Tandem Diabetes Care Announces Expanded Pediatric Indication of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology
Jun 17, 2020
SAN DIEGO --(BUSINESS WIRE)--Jun. 17, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of an expanded pediatric indication for the t:slim X2™ insulin pump with Control-IQ™
Tandem Diabetes Care Presents Positive Real-world Data from Automated Insulin Delivery Systems at American Diabetes Association Scientific Sessions
Jun 13, 2020
SAN DIEGO --(BUSINESS WIRE)--Jun. 13, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from early use of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology,
Tandem Diabetes Care Appoints Dr. Kathleen McGroddy-Goetz to Board of Directors
Jun 04, 2020
SAN DIEGO --(BUSINESS WIRE)--Jun. 4, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Kathleen McGroddy-Goetz , Ph.D., as an independent member of its Board of Directors effective June 8, 2020 . Dr.
Tandem Diabetes Care Announces Upcoming Virtual Conference Presentations
May 29, 2020
SAN DIEGO --(BUSINESS WIRE)--May 29, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan , president and chief executive officer, will present a company update at the following virtual investor conferences:
Tandem Diabetes Care to Hold Virtual-Only 2020 Annual Meeting of Stockholders
May 18, 2020
SAN DIEGO --(BUSINESS WIRE)--May 18, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”) will be held in a virtual-only format due to continued public health
Tandem Diabetes Care Announces Pricing of $250.0 Million of Convertible Senior Notes Due 2025
May 13, 2020
SAN DIEGO --(BUSINESS WIRE)--May 13, 2020-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem” or, the “Company”) announced today the pricing of $250.0 million aggregate principal amount of 1.50 percent Convertible Senior Notes due 2025 (the “Notes”) in a private placement to persons reasonably
Tandem Diabetes Care Announces Proposed Offering of $250.0 Million of Convertible Senior Notes Due 2025
May 12, 2020
SAN DIEGO --(BUSINESS WIRE)--May 12, 2020-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem” or, the “Company”) announced today that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”)
Tandem Diabetes Care Announces Upcoming Virtual Conference Presentations
May 07, 2020
SAN DIEGO --(BUSINESS WIRE)--May 7, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan , president and chief executive officer, will present a company update at the following virtual investor conferences:
Tandem Diabetes Care Announces First Quarter 2020 Financial Results
Apr 30, 2020
Second Quarter 2020 Sales Guidance Provided, Annual Guidance Withdrawn SAN DIEGO --(BUSINESS WIRE)--Apr. 30, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2020 .
Tandem Diabetes Care to Announce First Quarter 2020 Financial Results on April 30, 2020
Apr 09, 2020
SAN DIEGO --(BUSINESS WIRE)--Apr. 9, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2020 results after the financial markets close on Thursday, April 30, 2020 .
Tandem Diabetes Care Announces Security Incident with Five Employee Email Accounts
Mar 16, 2020
SAN DIEGO --(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM) today announced that it will be notifying its customers of an information security incident involving five Tandem employee email accounts. On January 17, 2020 , the Company learned that an unauthorized user gained access to an
Tandem Diabetes Care Announces FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller
Mar 02, 2020
SAN DIEGO --(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of its Basal-IQ™ technology as an interoperable automated glycemic controller (iAGC).
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2019 Financial Results and 2020 Financial Guidance
Feb 24, 2020
SAN DIEGO --(BUSINESS WIRE)--Feb. 24, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2019 and financial guidance for the year ending December 31, 2020 .
Data Presented at International Diabetes Conference Further Demonstrate Benefits of Tandem Diabetes Care Automated Insulin Delivery Technologies
Feb 20, 2020
MADRID --(BUSINESS WIRE)--Feb. 20, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced positive data presented today on its automated insulin delivery technologies, including data from a study of the t:slim X2™ insulin pump with
Tandem Diabetes Care Announces Upcoming Conference Presentations
Feb 14, 2020
SAN DIEGO --(BUSINESS WIRE)--Feb. 14, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming investor conferences: SVB Leerink 9 th Annual Global Healthcare Conference on
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
Jan 27, 2020
SAN DIEGO --(BUSINESS WIRE)--Jan. 27, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2019 results after the financial markets close on Monday, February 24, 2020 .
Displaying 1 - 20 of 222